Sold as Verquvo, the medication can help patients reduce their risk of cardiovascular death or hospitalization for heart failure.
The authors examined data from more than 1.2 million patients, tracking individuals who had previously been hospitalized for heart failure and then returned later due to COVID-19.
Researchers were able to predict, with considerable accuracy, each patient's 5- and 10-year risk of heart failure.
The researchers, sharing their work in the American Journal of Cardiology, suggested multiple reasons why this may be the case.
The document, published in the Journal of the American College of Cardiology, includes updated data and new treatment strategies.
New research, published in ESC Heart Failure, details why heart failure patients are a high-risk group and will benefit from vaccination.
"Being vaccinated is an important step in prevention," one specialist said.
The study’s authors tracked data from more than 13,000 patients with malignant melanoma and more than 25,000 patients with lung cancer.
When the patient had a history of stroke or heart failure, the researchers noted, their prediction model was less accurate.
Fracking was linked to an especially high risk of hospitalization for HFpEF and HFrEF patients.
Women were also seen less regularly by a cardiovascular specialist.
A 12-lead electrocardiogram revealed clear signs of myocardial injury related to COVID-19 and symptoms of heart failure.